Felty Syndrome Market
Number of pages: 100 | Report Format: PDF | Published date: March 16, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Route of Administration, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Felty Syndrome (FS) is an uncommon but potentially fatal illness defined by the presence of three conditions: rheumatoid arthritis (RA), an enlarged spleen (splenomegaly), and a low neutrophil count (i.e., neutropenia). Felty Syndrome is most commonly diagnosed in people aged 50 to 70 and is around three times more prevalent in individuals assigned to the female sex at birth. Felty Syndrome affects less than 1-3% of rheumatoid arthritis patients. This medical condition is most likely caused by a combination of factors, including higher hereditary predisposition and autoimmunity (when the body’s immune system erroneously targets its healthy cells for unclear reasons). Regardless of the main cause of Felty syndrome, recent research has shown that it occurs in a fraction of rheumatoid arthritis patients, particularly those who have had the ailment for more than 10 years and those with a more severe type of the disorder. This syndrome can be clinically diagnosed and is usually suspected in people with a long history of rheumatoid arthritis, splenomegaly, and a low white blood cell count. Further tests, such as testing for rheumatoid-arthritis-associated autoantibodies (e.g., rheumatoid factor or anti-CCP antibody) and a complete blood count to reveal neutropenia, are usually used to confirm the diagnosis. To determine the size of the spleen, imaging procedures such as an abdominal ultrasound or computed tomography scan may be used. A bone marrow biopsy may also be necessary to differentiate Felty Syndrome from other illnesses, such as non-lymphoma Hodgkin’s and large granular lymphocyte leukemia. However, a lack of awareness of Felty Syndrome and the treatment methods for such a rare syndrome can hinder the overall growth of the global Felty syndrome market.
Felty Syndrome Market Dynamics
The global Felty syndrome market is estimated to depict slow and steady growth during the projected timeframe. The growth of the Felty Syndrome market can be majorly attributed to the continuously growing prevalence of long-standing rheumatoid arthritis across the globe, particularly in the aging population. Additionally, the global prevalence of bacterial infections is increasing due to the emergence of antibiotic-resistant bacteria. There is a growing emphasis on patient-centered care in managing Felty syndrome, which involves a collaborative approach between patients and healthcare providers to develop an individualized treatment plan based on the patient’s unique needs and preferences. In addition, there have been growing advancements in the treatment and/or therapies, such as biologics, combination therapy, stem cell transplant, and gene therapy. Biologic drugs (TNF inhibitors, IL-6 inhibitors, and B-cell inhibitors) have shown promising results in treating Felty syndrome. These drugs work by targeting specific components of the immune system that contribute to the development of the condition. Significant advancements have been made in developing new and effective treatments for rheumatoid arthritis, including biologics and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). These drugs are designed to specifically target the underlying causes of the disease, resulting in improved outcomes for patients. The cost of treating rheumatoid arthritis has been increasing, particularly with biologic drugs. This has resulted in a higher focus on cost-effectiveness and value-based healthcare in the RA treatment market. There is a growing emphasis on preventing bacterial infections through vaccination, infection control, and hygiene practices. This has led to increased investment in research and the development of new preventive measures. There has been a shift in the regulatory landscape for antibacterial drugs, with regulatory agencies, such as the FDA (Food and Drug Administration) and EMA (the European Medicines Agency), emphasizing safety and efficacy in approving novel antibacterial agents.
Felty Syndrome Market Ecosystem
The global Felty syndrome market has been analyzed from four perspectives: drug class, route of administration, distribution channel, and region.
Felty Syndrome Market by Drug Class
Based on drug class, the global Felty syndrome market can be further segmented into immunosuppressants, tumor necrosis factor-alpha (TNF-α) inhibitors, anti-inflammatories, and others.
The immunosuppressants segment is estimated to show lucrative growth during the forecast period of 2023 to 2031. DMARDs are a sub-segment of immunosuppressive and immunomodulatory agents and are highly utilized for treating Felty syndrome. DMARDs can be further sub-segmented into methotrexate, hydroxychloroquine, sulfasalazine, rituximab, and others. The growth of this segment can be attributed to the rising prevalence of long-standing rheumatoid arthritis among the population, increasing the demand for DMARDs for treatment. DMARDs in Felty syndrome are similar to their usage in RA, where they are often the first-line therapy. Methotrexate is the most commonly used DMARD in Felty syndrome. Methotrexate has been shown to improve joint symptoms, decrease the risk of infections, and increase white blood cell counts in patients with Felty syndrome. Other DMARDs used in Felty syndrome include sulfasalazine, leflunomide, and hydroxychloroquine. These drugs have been shown to improve joint symptoms and reduce inflammation in RA, and their usage in Felty syndrome is based on extrapolation from studies in RA patients.
TNF inhibitors are a class of drugs designed to block TNF’s action. They reduce inflammation and joint damage associated with RA and other autoimmune diseases. In Felty syndrome, TNF inhibitors have been shown to improve neutropenia (low white blood cell count) and decrease the risk of infections. In addition, TNF inhibitors can also reduce the size of the spleen, which is often enlarged in Felty syndrome. TNF inhibitors in Felty syndrome are generally reserved for patients who have not responded to conventional therapy or have severe disease. The response to TNF inhibitors can vary from patient to patient, and some patients may not respond. Therefore, careful patient response monitoring is essential to ensure effective treatment.
Felty Syndrome Market by Route of Administration
[768546345]
Based on the route of administration, the global Felty syndrome market can be segmented into oral, topical, and parenteral.
The oral segment accounts for the largest revenue share of the global market. Oral drugs are easier to administer than other forms of medication, such as topical and parenteral. Patients benefit from administrating the pills or capsules alone without needing regular healthcare visits for treatment procedures. Additionally, oral drugs can have systemic effects, as they can work throughout the body. They can target the underlying causes of inflammation and/or bacterial infection. Moreover, some patients may prefer oral medications over other forms of treatment because they are familiar with taking pills and feel more comfortable with this route of administration.
The parenteral route is administering medication directly into the body through injection or infusion, bypassing the gastrointestinal tract. Parenteral routes are absorbed quickly into the bloodstream, providing rapid onset of action, and are highly used in emergencies. Thus, the amount of medication that reaches the target organ or tissue is more predictable. The parenteral route can also provide accurate doses, as the medication delivered is controlled and precise. With parenteral medications, healthcare providers have greater control over drug delivery, as they can titrate the medication to achieve the desired effect.
Felty Syndrome Market by Distribution Channel
Based on the distribution channel, the global Felty syndrome market can be further segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment plays a significant role in the treatment of Felty syndrome and is an important contributor to the revenue growth of the Felty syndrome market. Hospital pharmacies can provide patients with a broader selection of pharmaceuticals, including biologics, that may not be available in other settings. This can assist in guaranteeing that patients receive the best therapy possible for their illnesses. Furthermore, hospital pharmacies can collaborate with other healthcare experts, such as rheumatologists and infection specialists, to offer coordinated and individualized care for Felty syndrome patients. This can lead to improved treatment results and patient satisfaction. These pharmacies may educate patients about their drugs and how to take them correctly, improving medication adherence and lowering the chance of adverse outcomes. Furthermore, hospital pharmacies may monitor patients’ drugs and help with side effects and other concerns that may emerge during therapy. This can assist in guaranteeing that patients receive the best possible care and that treatment outcomes improve. Additionally, these pharmacies can engage in clinical studies and other Felty syndrome-related research activities. This may help create novel medicines and therapies for the condition, benefiting patients and boosting market revenue growth.
Felty Syndrome Market by Region
Based on the region, the global Felty syndrome market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America leads the Felty syndrome market in terms of revenue, which is projected to continue its dominance during the forecast period. Furthermore, the region’s high disposable income has accelerated the growth of the healthcare business due to the capacity to invest in highly complex medicine that meets the population’s unique medical demands, further accelerating market expansion in the region.
Asia Pacific is expected to be an emerging region in the projection period. This is due to increased long-standing rheumatoid arthritis, which can further lead to Felty syndrome. Additionally, an increase in the number of government initiatives to improve public awareness about the negative consequences of long-term psoriasis drives market expansion in the region.
Felty Syndrome Market Competitive Landscape
The prominent players operating in the global Felty syndrome market are:
AbbVie Inc., Amgen Inc., Novartis AG, Merck & Co. Inc., and Bristol-Myers Squibb are among the key players in the global Felty syndrome market.
The immunosuppressants segment dominates the global Felty syndrome market.
Asia Pacific is expected to observe the highest revenue growth in the Felty syndrome market during the forecast period.
Lack of awareness among the population is one of the major restraining factors to the global market revenue growth.
Felty Syndrome is defined as rheumatoid arthritis in combination with splenomegaly and leukopenia.
*Insights on financial performance are subject to the availability of information in the public domain